AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs for Esophageal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AGENT-797’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Esophageal Cancer

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AGENT-797 overview

AGENT-797 is under development for the treatment of moderate to severe acute respiratory syndrome due to COVID-19 and influenza, solid tumor, gastric cancer, chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, non-small cell lung cancer, cervical cancer, colorectal cancer, kidney cancer (renal cell cancer), thymoma (thymic epithelial tumor), transitional cell cancer (urothelial cell cancer), duodenal cancer, lung cancer, ocular melanoma pancreatic cancer, rectal cancer, bile duct cancer (cholangiocarcinoma), testicular cancer, prostate cancer, relapsed/refractory multiple myeloma, head and neck squamous cell carcinoma, hepatocellular cancer, graft versus host disease (autoimmune disease), esophageal cancer and adenocarcinoma of gastroesophageal junction. The drug candidate comprises of allogenic invariant natural killer T-cells (iNKT). It is administered through intravenous route.
It was also under development for the treatment of metastatic melanoma.

MiNK Therapeutics overview

MiNK Therapeutics, a subsidiary of Agenus Inc, is a biopharmaceutical company that develops and commercializes allogeneic, invariant natural killer T cell therapies for the treatment of cancer. The company is headquartered in New York City, New York, the US.

For a complete picture of AGENT-797’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.